Mistral Ventures Inc (PINK:MILV) recently “acquired” Nature’s Bioceuticals. The transaction was effectively a reverse merger. A week after that, MILV started bombarding traders with press releases and some promotional campaigns started.
Yesterday, MILV closed down 4.44% at $0.084 with approximately 57 million shares traded after announcing the company has decided to forgo filing an IND and NDA applications with the FDA, and instead take steps to begin manufacturing and marketing of the COPD formula as a dietary supplement.[BANNER]
The acquisition of a “ground breaking Breathing Formula” is just one of the claims MILV has put forth in the past week.
Other than press releases claiming the company has entered into huge markets, and the promotions, MILV hasn’t got much to go its way.
The company is using an alternative reporting standard and doesn’t have to file 8-K forms. So far, all that traders have to go on are the announcements.
If the claims of MILV prove factual, shareholders could see some returns, but at this point there is just very little certain about MILV.
